BACKGROUND AND PURPOSE: Quercetin is anti-inflammatory in macrophages by inhibiting lipopolysaccharide (LPS)-mediated increases in cytokine and nitric oxide production but there is little information regarding the corresponding effect on the vasculature. We have examined the effect of quercetin, and its principal human metabolites, on inflammatory changes in the porcine isolated coronary artery. EXPERIMENTAL APPROACH: Porcine coronary artery segments were incubated overnight at 37°C in modified Krebs-Henseleit solution with or without 1µg·mL(-1) LPS. Some segments were also co-incubated with quercetin-related flavonoids or Bay 11-7082, an inhibitor of NFκB. Changes in isometric tension of segments to vasoconstrictor and vasodilator agents were recorded. Nitrite content of the incubation solution was estimated using the Griess reaction, while inducible nitric oxide synthase was identified immunohistochemically. KEY RESULTS: Lipopolysaccharide reduced, by 35-50%, maximal contractions to KCl and U46619, thromboxane A(2) receptor agonist, and impaired endothelium-dependent relaxations to substance P. Nitrite content of the incubation medium increased 3- to 10-fold following exposure to LPS and inducible nitric oxide synthase was detected in the adventitia. Quercetin (0.1-10µM) opposed LPS-induced changes in vascular responses, nitrite production and expression of inducible nitric oxide synthase. Similarly, 10µM Bay 11-7082, 10µM quercetin 3'-sulphate and 10µM quercetin 3-glucuronide prevented LPS-induced changes, while myricetin (10µM) was inactive. Myricetin (10µM) prevented quercetin-induced modulation of LPS-mediated nitrite production. CONCLUSION AND IMPLICATIONS: Quercetin, quercetin 3'-suphate and quercetin 3-glucuronide, exerted anti-inflammatory effects on the vasculature, possibly through a mechanism involving inhibition of NFκB. Myricetin-induced antagonism of the effect of anti-inflammatory action of quercetin merits further investigation.
BACKGROUND AND PURPOSE:Quercetin is anti-inflammatory in macrophages by inhibiting lipopolysaccharide (LPS)-mediated increases in cytokine and nitric oxide production but there is little information regarding the corresponding effect on the vasculature. We have examined the effect of quercetin, and its principal human metabolites, on inflammatory changes in the porcine isolated coronary artery. EXPERIMENTAL APPROACH: Porcine coronary artery segments were incubated overnight at 37°C in modified Krebs-Henseleit solution with or without 1µg·mL(-1) LPS. Some segments were also co-incubated with quercetin-related flavonoids or Bay 11-7082, an inhibitor of NFκB. Changes in isometric tension of segments to vasoconstrictor and vasodilator agents were recorded. Nitrite content of the incubation solution was estimated using the Griess reaction, while inducible nitric oxide synthase was identified immunohistochemically. KEY RESULTS:Lipopolysaccharide reduced, by 35-50%, maximal contractions to KCl and U46619, thromboxane A(2) receptor agonist, and impaired endothelium-dependent relaxations to substance P. Nitrite content of the incubation medium increased 3- to 10-fold following exposure to LPS and inducible nitric oxide synthase was detected in the adventitia. Quercetin (0.1-10µM) opposed LPS-induced changes in vascular responses, nitrite production and expression of inducible nitric oxide synthase. Similarly, 10µM Bay 11-7082, 10µM quercetin 3'-sulphate and 10µM quercetin 3-glucuronide prevented LPS-induced changes, while myricetin (10µM) was inactive. Myricetin (10µM) prevented quercetin-induced modulation of LPS-mediated nitrite production. CONCLUSION AND IMPLICATIONS: Quercetin, quercetin 3'-suphate and quercetin 3-glucuronide, exerted anti-inflammatory effects on the vasculature, possibly through a mechanism involving inhibition of NFκB. Myricetin-induced antagonism of the effect of anti-inflammatory action of quercetin merits further investigation.
Authors: Francisco Pérez-Vizcaíno; Manuel Ibarra; Angel L Cogolludo; Juan Duarte; Francisco Zaragozá-Arnáez; Laura Moreno; Gustavo López-López; Juan Tamargo Journal: J Pharmacol Exp Ther Date: 2002-07 Impact factor: 4.030
Authors: E P Garvey; J A Oplinger; E S Furfine; R J Kiff; F Laszlo; B J Whittle; R G Knowles Journal: J Biol Chem Date: 1997-02-21 Impact factor: 5.157
Authors: Paul A Kroon; Michael N Clifford; Alan Crozier; Andrea J Day; Jennifer L Donovan; Claudine Manach; Gary Williamson Journal: Am J Clin Nutr Date: 2004-07 Impact factor: 7.045
Authors: Igor A Schepetkin; Andrew G Ramstead; Liliya N Kirpotina; Jovanka M Voyich; Mark A Jutila; Mark T Quinn Journal: Phytother Res Date: 2016-05-24 Impact factor: 5.878
Authors: Hiren P Amin; Charles Czank; Saki Raheem; Qingzhi Zhang; Nigel P Botting; Aedín Cassidy; Colin D Kay Journal: Mol Nutr Food Res Date: 2015-04-30 Impact factor: 5.914
Authors: Daniele Del Rio; Ana Rodriguez-Mateos; Jeremy P E Spencer; Massimiliano Tognolini; Gina Borges; Alan Crozier Journal: Antioxid Redox Signal Date: 2012-08-27 Impact factor: 8.401
Authors: Emily F Warner; Qingzhi Zhang; K Saki Raheem; David O'Hagan; Maria A O'Connell; Colin D Kay Journal: J Nutr Date: 2016-02-03 Impact factor: 4.798